These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 38791518)

  • 1. Available Therapeutic Options for Corneal Neovascularization: A Review.
    Drzyzga Ł; Śpiewak D; Dorecka M; Wyględowska-Promieńska D
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corneal neovascularization: updates on pathophysiology, investigations & management.
    Sharif Z; Sharif W
    Rom J Ophthalmol; 2019; 63(1):15-22. PubMed ID: 31198893
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current treatments for corneal neovascularization].
    Benayoun Y; Petellat F; Leclerc O; Dost L; Dallaudière B; Reddy C; Robert PY; Salomon JL
    J Fr Ophtalmol; 2015 Dec; 38(10):996-1008. PubMed ID: 26522890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization.
    Chaoran Z; Zhirong L; Gezhi X
    Graefes Arch Clin Exp Ophthalmol; 2011 Oct; 249(10):1493-501. PubMed ID: 21574021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-based antiangiogenic applications for corneal neovascularization.
    Liu S; Romano V; Steger B; Kaye SB; Hamill KJ; Willoughby CE
    Surv Ophthalmol; 2018; 63(2):193-213. PubMed ID: 29080632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corneal neovascularization: an anti-VEGF therapy review.
    Chang JH; Garg NK; Lunde E; Han KY; Jain S; Azar DT
    Surv Ophthalmol; 2012 Sep; 57(5):415-29. PubMed ID: 22898649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-targeted and localized AAV5-DCN and AAV5-PEDF combination gene therapy abrogates corneal fibrosis and concurrent neovascularization in rabbit eyes in vivo.
    Mohan RR; Gupta S; Kumar R; Sinha NR; Landreneau J; Sinha PR; Tandon A; Chaurasia SS; Hesemann NP
    Ocul Surf; 2024 Apr; 32():13-25. PubMed ID: 38191093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model.
    Mirabelli P; Peebo BB; Xeroudaki M; Koulikovska M; Lagali N
    Exp Eye Res; 2014 Aug; 125():118-27. PubMed ID: 24933712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study.
    Cursiefen C; Viaud E; Bock F; Geudelin B; Ferry A; Kadlecová P; Lévy M; Al Mahmood S; Colin S; Thorin E; Majo F; Frueh B; Wilhelm F; Meyer-Ter-Vehn T; Geerling G; Böhringer D; Reinhard T; Meller D; Pleyer U; Bachmann B; Seitz B
    Ophthalmology; 2014 Sep; 121(9):1683-92. PubMed ID: 24811963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization.
    Cursiefen C; Rummelt C; Küchle M
    Cornea; 2000 Jul; 19(4):526-33. PubMed ID: 10928772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments for corneal neovascularization: a review.
    Gupta D; Illingworth C
    Cornea; 2011 Aug; 30(8):927-38. PubMed ID: 21389854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway.
    Shen M; Zhou XZ; Ye L; Yuan Q; Shi C; Zhu PW; Jiang N; Ma MY; Yang QC; Shao Y
    Int J Mol Med; 2018 Aug; 42(2):769-778. PubMed ID: 29717775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current trends in the management of corneal neovascularization.
    Rangu N; Dang DH; Riaz KM
    Curr Opin Ophthalmol; 2024 Jul; 35(4):329-342. PubMed ID: 38813739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting Edge: Novel Treatment Options Targeting Corneal Neovascularization to Improve High-Risk Corneal Graft Survival.
    Cursiefen C; Hos D
    Cornea; 2021 Dec; 40(12):1512-1518. PubMed ID: 34116541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.
    Zhang C; Yin Y; Zhao J; Li Y; Wang Y; Zhang Z; Niu L; Zheng Y
    Int J Nanomedicine; 2022; 17():4911-4931. PubMed ID: 36267540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corneal neovascularization and contemporary antiangiogenic therapeutics.
    Hsu CC; Chang HM; Lin TC; Hung KH; Chien KH; Chen SY; Chen SN; Chen YT
    J Chin Med Assoc; 2015 Jun; 78(6):323-30. PubMed ID: 25687646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VEGF Treatment in Corneal Diseases.
    Giannaccare G; Pellegrini M; Bovone C; Spena R; Senni C; Scorcia V; Busin M
    Curr Drug Targets; 2020; 21(12):1159-1180. PubMed ID: 32189591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents.
    Hosseini H; Nejabat M
    Med Hypotheses; 2007; 68(4):799-801. PubMed ID: 17107753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corneal neovascularization and biological therapy.
    Voiculescu OB; Voinea LM; Alexandrescu C
    J Med Life; 2015; 8(4):444-8. PubMed ID: 26664467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corneal neovascularization.
    Nicholas MP; Mysore N
    Exp Eye Res; 2021 Jan; 202():108363. PubMed ID: 33221371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.